Switzerland· 65730003
Bexsero
A meningokokkus b, multikomponenten-impfstoff product containing proteinum fusionatum nhba neisseriae meningitidis b, proteinum nada neisseriae meningitidis b, proteinum fusionatum fhbp neisseriae meningitidis b, vesicula membranae exterioris (omv) ex neisseria meningitidis b (stamm: nz98/254), registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Meningokokkus b, multikomponenten-impfstoff is registered in 11 of 19 countries.
Countries holding a registration under ATC J07AH09 (meningokokkus b, multikomponenten-impfstoff), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 7 of them publish a price we can compare per daily dose
Meningokokkus b, multikomponenten-impfstoff · ATC J07AH09
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- proteinum fusionatum NHBA neisseriae meningitidis B, proteinum NadA neisseriae meningitidis B, proteinum fusionatum fHbp neisseriae meningitidis B, vesicula membranae exterioris (OMV) ex Neisseria meningitidis B (Stamm: NZ98/254)
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- J07AH09
- ATC class
- Meningokokkus B, Multikomponenten-Impfstoff
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680657300031Fertspr 1 DosCHF 98.7
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07AH09
Meningokokkus b, multikomponenten-impfstoff, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/da19a9bd-9754-4707-8323-ac12ba92b5a0 GET /v1/drugs/da19a9bd-9754-4707-8323-ac12ba92b5a0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "proteinum fusionatum nhba neisserii meningitidii b 50 mcg + proteinum nada neisserii meningitidii b 50 mcg + proteinum fusionatum fhbp neisserii meningitidii b 50 mcg + neisseria meningitidis b outer membrane vesicle 25 mcg",
"valid_from": "2026-02-01",
"limitations": "[{\"description\":\"Kostenübernahme bei Säuglingen und Kleinkindern ab 2 Monaten bis 5 Jahren als empfohlene ergänzende Impfung.<br>\\nKostenübernahme bei Kindern und Jugendlichen ab 11 Jahren bis 20 Jahren als empfohlene ergänzende Impfung.<br>\\nKostenübernahme bei Personen ab 2 Monaten bis 24 Jahren als empfohlene Impfung für Risikogruppen (Personen mit einem erhöhten Risiko für eine invasive Erkrankung oder Exposition).<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2026-02-01\",\"validTo\":\"2029-01-31\"}]",
"galenic_form": "Inj Susp 0.5 ml",
"therapeutic_area": null,
"sl_inclusion_date": "2023-01-01",
"self_retention_pct": 10
}See everything about meningokokkus b, multikomponenten-impfstoff.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.